Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromopride + simethicone is a fixed-dose combination of two agents used to manage gastrointestinal symptoms. Bromopride is a substituted benzamide and dopamine antagonist with prokinetic and antiemetic properties, closely related to metoclopramide. It acts primarily by blocking dopamine D2 receptor in the chemoreceptor trigger zone and enhancing gastrointestinal motility, making it effective for treating nausea, vomiting (including postoperative), gastroesophageal reflux disease (GERD), and as preparation for GI procedures[4][7]. Simethicone is an oral anti-foaming agent that relieves symptoms of excess gas such as bloating, pressure, or discomfort in the stomach and intestines. It works by reducing surface tension of gas bubbles in the gut, causing them to combine into larger bubbles that can be passed more easily[2][3][5]. The combination is used primarily for symptomatic relief of dyspepsia, flatulence, bloating, nausea/vomiting associated with functional GI disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromopride + simethicone.